BioSpace News Archive

The bacterial conjunctivitis drug market in U.S. is extremely fragmented in nature as various players are operating in the market.

The rivalry between Sun Pharmaceuticals Ltd., Valeant Pharmaceuticals International Inc., Mylan N.V., F. Hoffmann-La Roche Ltd., and Merck & Co. Inc. characterizes the competitive landscape present in the global basal cell carcinoma treatment market, states a new research study by Transparency Market Research (TMR).

KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 12, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the second quarter 2020. Conference Call Information: Interested participants and investors may access the conference call b

ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency

POINT Biopharma Inc., a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, has completed a USD $20 Million Series A financing round.

- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 - - Plan to Initiate New Clinical Study in Ulcerative Colitis in Q3 2020 - LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced financial results for the second quarter 2020 and provided a

- Further advances in recurrent glioblastoma program including submission of End of Phase 2 (“EOP2”) meeting package for MDNA55 - EOP2 meeting scheduled for 29 th September, 2020 with FDA input expected in calendar Q4 2020 - Presented new preclinical data demonstrating the favorable safety profile and best-in-class potential of MDNA11 at ASCO 2020 - Depository Trust Certification (“DTC”) approved in July 2020 TORONTO and HOUSTON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Medicenna Th

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial and operating results for the second quarter of 2020. Second Quarter 2020 Summary Second quarter 2020 revenue was $9.7 million, compared to second quarter 2019 revenue of $16.6 million Seco

Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the addition of four clinical trial sites to its ongoing AuroLase® pivotal study. T

Potential Collaboration in Diabetic Peripheral Neuropathy and Chemotherapy-Induced Peripheral Neuropathy for ASEAN Region